Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Lexeo Therapeutics (LXEO) Shares Outstanding (Weighted Average) (2022 - 2026)

Lexeo Therapeutics' Shares Outstanding (Weighted Average) history spans 2 years, with the latest figure at $5.4 million for Q4 2023.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 228.42% to $5.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $5.4 million, a 228.42% increase, with the full-year FY2023 number at $5.4 million, up 228.42% from a year prior.
  • Shares Outstanding (Weighted Average) hit $5.4 million in Q4 2023 for Lexeo Therapeutics, up from $1.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for LXEO hit a ceiling of $5.4 million in Q4 2023 and a floor of $1.6 million in Q1 2023.